Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Cell Therapy Manufacturing Market (3rd Edition), 2019 - 2030Roots Analysis has announced the addition of "Cell Therapy Manufacturing Market (3rd Edition), 2019 - 2030" report to its list of offerings.
By: Roots Analysis Key Market Insights More than 160 organizations claim to be engaged in cell therapy manufacturing The market landscape is dominated by industry players, representing more than 60% of the total number of stakeholders. Amongst these, over 55 are large or mid-sized firms (having more than 50 employees). Presently, 70+ companies have commercial scale capacity As majority of the cell therapy products are in clinical trials, the demand is high at this scale. However, it is worth noting that several players (~50%) have already developed commercial scale capacity for cell therapies. Europe is currently considered a current hub for cell therapy production More than 220 manufacturing facilities have been established by various players, worldwide; of these, 35% are in Europe, followed by those based in North America. Other emerging regions include Australia, China, Japan, Singapore. 50+ facility expansions reported between 2015-2019 More than 85% of the expansions are related to setting up of new facilities across different regions. Maximum expansion activity was observed in the US and in certain countries within the Asia Pacific regions. 20+ companies offer automated solutions to cell therapy developers Players that claim to offer consultancy services related to automation include (in alphabetical order) Berkeley Lights, Cesca Therapeutics, Ferrologix, FluDesign Sonics, GE Healthcare and Terumo BCT. Further, we identified players, namely (in alphabetical order) Fraunhofer Institute for Manufacturing Engineering and Automation IPA, Invetech, KMC Systems, Mayo Clinic Center for Regenerative Medicine and RoosterBio, that offer consultancy solutions related to automation. Partnership activity has grown at an annualized rate of 16%, between 2014 and 2018 More than 200 agreements have been inked in the last 5 years; majority of these were focused on the supply of cell-based therapy products for clinical trials. Other popular types of collaboration models include manufacturing process development agreements (16%), services agreements (12%) and acquisitions (10%). By 2030, developed geographies will capture over 60% of the market share Asia Pacific is anticipated to capture the major share (~36%) of the market by 2030. It is also important to highlight that financial resources, technical expertise and established infrastructure is likely to drive cell therapy manufacturing market in Europe. For additional details, please visit https://www.rootsanalysis.com/ Contact: Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091o https://www.rootsanalysis.com/ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|